NCT07018050 - Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

September 12, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

July 31, 2028

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG

QLS32015

QLS32015 will be administered subcutaneously

DRUG

Pomalidomide

Pomalidomide will be self-administered as a single dose orally

DRUG

Dexamethasone

Dexamethasone will be administered orally or intravenously

DRUG

QL2109 or Daratumumab

QL2109 or Daratumumab will be administered subcutaneously.

DRUG

Bortezomib

Bortezomib will be administered subcutaneously

DRUG

Lenalidomide

Lenalidomide will be self-administered as a single dose orally

Trial Locations (1)

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY